In this brief review, we discuss immune tolerance as a factor that determines the magnitude and quality of serum antibody responses to HIV-1 infection and vaccination in the context of recent work. We propose that many conserved, neutralizing epitopes of HIV-1 are weakly immunogenic because they mimic host antigens. In consequence, B cells that strongly bind these determinants are removed by the physiological process of immune tolerance. This structural mimicry may represent a significant impediment to designing protective HIV-1 vaccines, but we note that several vaccine strategies may be able to mitigate this evolutionary adaptation of HIV and other microbial pathogens. Keywords HIV-1 vaccines; immune tolerance; broadly neutralizing antibo...
So far, the development of a human immunodeficiency virus (HIV) vaccine has been unsuccessful. Howev...
The partial efficacy reported in the RV144 HIV vaccine trial in 2009 has driven the HIV vaccine fiel...
Abstract Despite enormous efforts no HIV-1 vaccine has been developed that elicits broadly neutraliz...
In this brief review, we discuss immune tolerance as a factor that determines the magnitude and qual...
Abstract A central puzzle in HIV-1 research is the inability of vaccination or even infection to rel...
Neutralizing antibodies can protect from infection by immunodeficiency viruses. However, the inducti...
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive. There are...
<p>Many human monoclonal antibodies that neutralize multiple clades of HIV-1 are polyreactive and bi...
The ability to induce neutralizing antibodies is generally thought to be of great importance for vac...
Recent findings have brought optimism that development of a successful human immunodeficiency virus ...
Induction of broadly neutralising antibodies (bnAbs) capable of inhibiting infection with diverse va...
AbstractAlthough the majority of primary HIV-1 variants can be neutralized by broadly neutralizing a...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
A primary correlate of protection for most effective viral vaccines is induction of antibodies with ...
Abstract: The mechanism of antibody-mediated protection is a major focus of HIV-1 vaccine developmen...
So far, the development of a human immunodeficiency virus (HIV) vaccine has been unsuccessful. Howev...
The partial efficacy reported in the RV144 HIV vaccine trial in 2009 has driven the HIV vaccine fiel...
Abstract Despite enormous efforts no HIV-1 vaccine has been developed that elicits broadly neutraliz...
In this brief review, we discuss immune tolerance as a factor that determines the magnitude and qual...
Abstract A central puzzle in HIV-1 research is the inability of vaccination or even infection to rel...
Neutralizing antibodies can protect from infection by immunodeficiency viruses. However, the inducti...
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive. There are...
<p>Many human monoclonal antibodies that neutralize multiple clades of HIV-1 are polyreactive and bi...
The ability to induce neutralizing antibodies is generally thought to be of great importance for vac...
Recent findings have brought optimism that development of a successful human immunodeficiency virus ...
Induction of broadly neutralising antibodies (bnAbs) capable of inhibiting infection with diverse va...
AbstractAlthough the majority of primary HIV-1 variants can be neutralized by broadly neutralizing a...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
A primary correlate of protection for most effective viral vaccines is induction of antibodies with ...
Abstract: The mechanism of antibody-mediated protection is a major focus of HIV-1 vaccine developmen...
So far, the development of a human immunodeficiency virus (HIV) vaccine has been unsuccessful. Howev...
The partial efficacy reported in the RV144 HIV vaccine trial in 2009 has driven the HIV vaccine fiel...
Abstract Despite enormous efforts no HIV-1 vaccine has been developed that elicits broadly neutraliz...